Expanded Access Programme Assessing Safety and Efficacy of Nivolumab in Italian Patients with Metastatic Renal Cell Carcinoma in a Real World Setting

Trial Profile

Expanded Access Programme Assessing Safety and Efficacy of Nivolumab in Italian Patients with Metastatic Renal Cell Carcinoma in a Real World Setting

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Most Recent Events

    • 12 Sep 2017 Results (n=195) assessing the feasibility of nivolumab in the elderly and very elderly patients, presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Sep 2017 Results (n=346) assessing the prognostic impact of inflammatory indexes on clinical outcomes in patients with metastatic renal cell cancer treated with nivolumab, presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Sep 2017 Results (n=100) of analysis about the subgroup of patients treated beyond initial progressive disease presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top